TSX gains after CPI shows US inflation rose 3%
Investing.com - Canaccord Genuity raised its price target on GRAIL, Inc. (NASDAQ:GRAL) to $85.00 from $75.00 on Tuesday, while maintaining a Buy rating on the stock. The company’s shares have shown remarkable momentum, surging over 160% in the past six months, with InvestingPro data showing a current trading price of $83.71.
The price target increase follows the company’s announcement of performance and safety results from its registrational PATHFINDER 2 study, which were released after market close on Friday, October 17, 2025. With GRAL’s next earnings report due on November 18, investors seeking deeper insights can access comprehensive analysis through InvestingPro’s detailed research reports.
GRAIL’s Galleri multi-cancer early detection (MCED) test showed a 61.6% positive predictive value in the study, an improvement from the 43.1% recorded in PATHFINDER 1. The test also demonstrated 99.6% specificity and 40.4% "episode" sensitivity.
The research firm cited "relatively positive study results" and over $400 million pending addition to the company’s balance sheet as factors supporting its bullish stance, despite noting that "multiple questions remain regarding the perspective of regulators and clinicians."
GRAIL plans to submit its application to the FDA in the first half of 2026, though Canaccord Genuity indicated uncertainty about whether the improved data will be sufficient for regulatory approval.
In other recent news, Grail Inc. has reported significant developments in its cancer detection efforts. The company announced positive long-term results from its SYMPLIFY study, revealing that 35.4% of participants initially classified as having false positive results were later diagnosed with cancer within 24 months. This finding has increased the positive predictive value of Grail’s Galleri test to 84.2%. Additionally, Grail has secured $325 million in private placement financing, attracting investments from major firms such as Deep Track Capital and Farallon Capital Management.
In a strategic move, Samsung C&T and Samsung Electronics have invested $110 million in Grail, aiming to bring the Galleri test to key Asian markets, including South Korea, Japan, and Singapore. The investment is priced at $70.05 per share and involves a partnership where Samsung C&T will serve as the exclusive distributor in South Korea. These developments highlight Grail’s progress in enhancing its cancer detection technology and expanding its market reach.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.